JP2016501204A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501204A5
JP2016501204A5 JP2015543145A JP2015543145A JP2016501204A5 JP 2016501204 A5 JP2016501204 A5 JP 2016501204A5 JP 2015543145 A JP2015543145 A JP 2015543145A JP 2015543145 A JP2015543145 A JP 2015543145A JP 2016501204 A5 JP2016501204 A5 JP 2016501204A5
Authority
JP
Japan
Prior art keywords
absent
aib
beta
lys
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015543145A
Other languages
English (en)
Japanese (ja)
Other versions
JP6525456B2 (ja
JP2016501204A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/071077 external-priority patent/WO2014081872A1/en
Publication of JP2016501204A publication Critical patent/JP2016501204A/ja
Publication of JP2016501204A5 publication Critical patent/JP2016501204A5/ja
Application granted granted Critical
Publication of JP6525456B2 publication Critical patent/JP6525456B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015543145A 2012-11-20 2013-11-20 インスリン抵抗性のための改善されたペプチド製剤 Active JP6525456B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728649P 2012-11-20 2012-11-20
US61/728,649 2012-11-20
PCT/US2013/071077 WO2014081872A1 (en) 2012-11-20 2013-11-20 Improved peptide pharmaceuticals for insulin resistance

Publications (3)

Publication Number Publication Date
JP2016501204A JP2016501204A (ja) 2016-01-18
JP2016501204A5 true JP2016501204A5 (cg-RX-API-DMAC7.html) 2017-01-12
JP6525456B2 JP6525456B2 (ja) 2019-06-05

Family

ID=50776533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543145A Active JP6525456B2 (ja) 2012-11-20 2013-11-20 インスリン抵抗性のための改善されたペプチド製剤

Country Status (11)

Country Link
US (3) US11065304B2 (cg-RX-API-DMAC7.html)
EP (3) EP2922876B1 (cg-RX-API-DMAC7.html)
JP (1) JP6525456B2 (cg-RX-API-DMAC7.html)
KR (2) KR102365582B1 (cg-RX-API-DMAC7.html)
CN (3) CN118324870A (cg-RX-API-DMAC7.html)
AU (1) AU2013347975B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015011478B1 (cg-RX-API-DMAC7.html)
CA (1) CA2891931A1 (cg-RX-API-DMAC7.html)
DK (1) DK2922876T3 (cg-RX-API-DMAC7.html)
MX (2) MX360816B (cg-RX-API-DMAC7.html)
WO (1) WO2014081872A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134906A1 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR102365582B1 (ko) 2012-11-20 2022-02-18 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
ES2906975T3 (es) 2012-11-20 2022-04-21 Eumederis Pharmaceuticals Inc Productos farmacéuticos de péptidos mejorados
RS57531B1 (sr) 2012-12-21 2018-10-31 Sanofi Sa Derivati eksendina-4 kao dualni glp1/gip- ili trigonalni glp1/gip/glukagon agonisti
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
KR102542164B1 (ko) 2014-05-28 2023-06-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
KR102005456B1 (ko) 2015-06-30 2019-07-30 한미약품 주식회사 신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물
TW201706291A (zh) * 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
MX2018008128A (es) 2015-12-31 2018-12-06 Hanmi Pharm Ind Co Ltd Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 y gip.
MX2019000019A (es) * 2016-06-29 2019-05-06 Hanmi Pharm Ind Co Ltd Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo.
WO2018139991A1 (en) 2017-01-24 2018-08-02 Macregen, Inc. Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics
AU2018226872A1 (en) 2017-03-03 2019-09-05 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CA3086918A1 (en) * 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
JP7752619B2 (ja) * 2020-02-21 2025-10-10 スピットファイア ファーマ エルエルシー Glp-1rおよびgcgrアゴニスト、製剤、ならびに使用方法
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CN113461747B (zh) * 2021-07-12 2023-02-03 吉林化工学院 刺玫果中2个具有降血糖活性的化合物
CN119855586A (zh) * 2022-07-29 2025-04-18 加利福尼亚大学董事会 用于治疗代谢障碍的组合物和方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5661130A (en) * 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (ja) 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
DK2322229T3 (en) 2001-10-10 2017-03-27 Novo Nordisk As Remodeling and Glycoconjugation of Factor IX
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
EP1610813A4 (en) 2003-03-19 2009-07-01 Gen Hospital Corp CONFORMATION RESTRICTED PARATHORMONE WITH A HELIX STABILIZERS
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20110257096A1 (en) * 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
WO2006096426A2 (en) 2005-03-03 2006-09-14 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
JP2008539735A (ja) 2005-05-06 2008-11-20 バイエル・フアーマシユーチカルズ・コーポレーシヨン グルカゴン様ペプチド1(glp−1)受容体アンタゴニストおよびそれらの薬理学的使用方法
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
ES2336575T3 (es) * 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
US8454971B2 (en) 2007-02-15 2013-06-04 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5775450B2 (ja) 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴン/glp−1受容体コアゴニスト
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
PH12012501494A1 (en) * 2010-01-20 2012-10-22 Zealand Pharma As Treatment of cardiac conditions
WO2011117415A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
EA201390941A1 (ru) * 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
KR101453037B1 (ko) 2011-03-23 2014-10-21 주식회사 엘지화학 전극조립체 및 이의 제조방법
EP4286400A3 (en) 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
CA3134906A1 (en) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
JP2014011554A (ja) * 2012-06-28 2014-01-20 Seiichi Onoda 光線路監視方法、および光線路監視システム
KR102365582B1 (ko) 2012-11-20 2022-02-18 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
ES2906975T3 (es) * 2012-11-20 2022-04-21 Eumederis Pharmaceuticals Inc Productos farmacéuticos de péptidos mejorados
KR102542164B1 (ko) 2014-05-28 2023-06-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
CA3086918A1 (en) * 2018-01-03 2019-07-11 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of nash and other disorders
JP7752619B2 (ja) * 2020-02-21 2025-10-10 スピットファイア ファーマ エルエルシー Glp-1rおよびgcgrアゴニスト、製剤、ならびに使用方法

Similar Documents

Publication Publication Date Title
JP2016501204A5 (cg-RX-API-DMAC7.html)
JP2020073481A5 (cg-RX-API-DMAC7.html)
JP2014516037A5 (cg-RX-API-DMAC7.html)
JP2020143066A5 (cg-RX-API-DMAC7.html)
US8343927B2 (en) Pharmaceutical compositions for prevention of overdose or abuse
JP6525456B2 (ja) インスリン抵抗性のための改善されたペプチド製剤
JP5584236B2 (ja) 神経ペプチドy受容体結合化合物を有する細胞毒性コンジュゲート
JP6290187B2 (ja) 癌の処置のためのタンパク質の部位特異的標識及び標的送達
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
JP2012067099A5 (cg-RX-API-DMAC7.html)
KR102542164B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
RU2013154047A (ru) Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности
JP2009533459A (ja) 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法
JP2017535527A5 (cg-RX-API-DMAC7.html)
CA2776302A1 (en) Neuropeptide-2 receptor (y-2r) agonists
JP7733664B2 (ja) Epi-x4系ペプチドおよびその誘導体
ES2805536T3 (es) Moléculas de neurotensina activadas y sus usos
WO2017212494A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
KR20080042045A (ko) 포유동물로의 인터페론 전달용 지질 구조물
JP2024545747A (ja) ペンタペプチドおよびその用途
JP2019520336A5 (cg-RX-API-DMAC7.html)
JP2009528303A5 (cg-RX-API-DMAC7.html)
WO2006101909A2 (en) Combination therapy for treating or preventing diseases
US6989371B1 (en) Bombesin analogs for treatment of cancer
JP2025186263A (ja) Epi-x4系ペプチドおよびその誘導体